Q2 2021 Results - Reimagining Medicine

Participants Financial performance Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations ZolgensmaⓇ - SMN1 gene replacement therapy Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients NCT03381729 STRONG (CL-102) Type 2 spinal muscular atrophy Phase 1 51 Safety and tolerability, incidence of adverse events Proportion of patients achieving Standing Milestone Change in Hammersmith Functional Motor Scale Open-label, single-arm, single-dose, intrathecal Patients with spinal muscular atrophy with 3 copies of SMN2 Cohort B: Q4-2019 (actual); Cohort C1: TBC Read-out Milesstone(s) Publication TBD NCT03837184 STRIVE Asia Pacific (CL-306) Type 1 spinal muscular atrophy Phase 3 2 Proportion of participants sitting without support Open-label, single-arm, single-dose, intravenous Patients with spinal muscular atrophy Type 1 H2-2021 TBD 91 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation